NCT05838183 Interstitial Lung Disease and Obstructive Sleep Apnea
| NCT ID | NCT05838183 |
| Status | Recruiting |
| Phase | — |
| Sponsor | Dan Liu |
| Condition | ILD OSA |
| Study Type | OBSERVATIONAL |
| Enrollment | 70 participants |
| Start Date | 2019-09-01 |
| Primary Completion | 2026-12-31 |
Eligibility & Interventions
Eligibility Fast-Check
Enter your details for a quick preliminary check. This does not replace medical advice.
What to Expect as a Participant
This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.
This trial targets 70 participants in total. It began in 2019-09-01 with a primary completion date of 2026-12-31.
⚠ This information is for research awareness only. Always consult your physician before joining any clinical trial. Participation is voluntary and you may withdraw at any time.
Brief Summary
Clinically, all patients with interstitial lung disease(ILD) were observed, and relevant clinical data were collected. Bronchoscopic specimens were collected according to the condition of the enrolled patients, and the rapid on site evaluation(ROSE) was evaluated, combined with the metagenomic next generation sequencing(mNGS) results of these patients. To observe the etiology and biological characteristics of exacerbation in patients with interstitial lung disease. All patients undergo polysomnography (PSG) and drug-induced sleep endoscopy(DISE). The biological specimens was obtained for molecular biology or other tests.We detected ZNF331, Claudin1, Claudin2, Claudin3, Claudin4, and IL22 as biomarkers to differentiate the diagnostic efficiency of OSA in ILD, ILD+OSA, OSA, and Ctrl groups, respectively
Eligibility Criteria
Inclusion criteria: * over 18 years old and under 80 years old. * Clinical diagnosis of interstitial lung disease or obstructive respiratory sleep apnea syndrome. * Patient is conscious and capable of signing informed consent. * The patient may wear a polysomnograph. Exclusion criteria: * malignant tumors. * severe heart failure. * uremia. * autoimmune diseases. * pulmonary embolism, and end-stage chronic obstructive pulmonary disease. * Patients with mental illnesscannot sign informed consent on their own.
Contact & Investigator
Frequently Asked Questions
Who can join the NCT05838183 clinical trial?
This trial is open to participants of all sexes, aged 18 Years or older, up to 80 Years, studying ILD OSA. Full inclusion and exclusion criteria are listed in the Eligibility Criteria section. Always confirm your eligibility with the research team before applying.
Is NCT05838183 currently recruiting?
Yes, NCT05838183 is actively recruiting participants. Contact the research team at liudan_nkdx@163.com for enrollment information.
Where is the NCT05838183 trial being conducted?
This trial is being conducted at Tianjin, China.
Who is sponsoring the NCT05838183 clinical trial?
NCT05838183 is sponsored by Dan Liu. The trial plans to enroll 70 participants.